Soccer Roundup: Wambach And U.S. Move A Step Closer To The Olympics The United States women’s national team has secured a berth in the semifinals of the regional qualifying competition for this summer’s Olympics in Beijing.... Read Full Article Advertising: Uncle Ben, Board Chairman The racially charged symbol for Uncle Ben’s rice products is taking center stage in a new campaign that makes him chairman of the company.... Read Full Article 50 Missing After Boat Sinks Off Bangladesh More than 50 people were missing after a boat, possibly being ferried by human traffickers, sank off a southern Bangladesh island bordering Myanmar waters.... Read Full Article Shock In Pakistani Enclaves In New York Whether they liked her or not, New York City’s Pakistani immigrants were mostly shaken by the assassination of Benazir Bhutto.... Read Full Article Adu Struggles For Playing Time In Europe Freddy Adu transferred to the Portuguese club last summer from Real Salt Lake and has played just 64 minutes over 2 1/2 months, appearing twice as a substitute.... Read Full Article |
Glaxos NewsF.D.A. Reviewing H.I.V. Drugs for Heart RiskThe Food and Drug Administration said that recent data show patients taking H.I.V. drugs from GlaxoSmithKline and Bristol-Myers Squibb may have increased risk of heart attack.Read Full Article Reckitt faces inquiries over ’plan’ to maintain Gaviscon’s dominanceReckitt Benckiser faces a series of investigations by competition and health regulators over an alleged secret plan to maintain a monopoly in the supply of Gaviscon, the lucrative heartburn medicine.<br/> <br/> Internal documents show that executives at Reckitt, the Hull-based drug and cleaning products company, plotted under the codename “Project Eric” to block rivals from selling cheaper generic copies of Gaviscon.<br/> <br/> One former senior executive said Reckitt had “cheated the NHS”. It is thought that a cheaper, generic version of Gaviscon could have saved the health service £40 million a year.<br/> <br/> E-mails between executives discuss how to “drag out as long as possible” the process of other companies being allowed to manufacture generic versions, and their intention to create “a further barrier to competitors” and “restrict entry for new competitors”.<br/> <br/> The company announced an internal investigation into the allegations, made by BBC2’s <i>Newsnight</i>, insisting that it was “a responsible company in the way it conducts its business”.<br/> <br/> A spokesman for the Office of Fair Trading said: “We are aware of the story and are considering whether there may be a competition case to answer.” The NHS Counter Fraud Service is also considering whether an inquiry falls within its remit, and the House of Commons Health Select Committee may also investigate.<br/> <br/> Kevin Barron, MP, chair of the committee, said he was “disturbed” by the e-mails. “I will be taking it back to the committee to look at,” he said.<br/> <br/> However, it is not clear whether any laws have been broken. One regulatory source said: “Members of the public might not find it particularly wholesome. It might be sharp practice and they may be sailing close to the wind, but that doesn’t mean it’s illegal.”<br/> <br/> Before a rival company can create a generic drug, the British National Formulary must give it an official title. Reckitt tried to claim Gaviscon was unique and such a title could not be issued. It objected in 2000, 2003, 2005 and 2006.<br/> <br/> The drug company also successfully lobbied the British Pharmacopoeia Commission (BPC), part of the Medicines and Healthcare Regulatory Agency, that for health and safety reasons, a detailed quality specification known as a monograph was needed.<br/> <br/> One Reckitt executive wrote: “Should we not drag it out as long as possible . . . £9 million of business is at stake”. The e-mails talk of “a clever idea” - to make a near-identical product with a different name. “There must be something we can dig out of the cupboard!” one executive wrote.<br/> <br/> Reckitt also tried to persuade doctors to prescribe the new Gaviscon Advance. In 2005 the industry’s watchdog found it guilty of unethical behaviour.<br/> <br/> The news comes shortly after the European Commission began an inquiry into whether pharmaceutical companies were employing illegal tactics to delay generic versions.<br/> <br/> In January, it raided the offices of some of the world’s largest drug companies, including Pfizer, GlaxoSmithKline, Astrazeneca, Johnson & Johnson, Merck & Co and Sanofi-Aventis. In 2005 AstraZeneca, the Anglo-Swedish drug manufacturer, was fined €60 million for trying to delay rival versions of its ulcer drug, Losec, thereby keeping prices artificially high.<br/> <br/> A spokesman for Reckitt said: “We are shocked by the allegations . . . and by the inappropriate sentiment expressed in some of the internal correspondence of 2003.” A spokesman for the BPC said it was “aware that the company would want to protect its market”. He added: “When Reckitt sought to protect the monograph being published with a legal challenge, the BPC rejected this request and proceeded with its publication.”Read Full Article String of blue chip upsets send FTSE plummetingGlaxoSmithKline unsettled an already falling London market this afternoon with a warning that falling sales of its key Avandia diabetes drug combined with growing competition from copycat drugs in the US would knock about 5 per cent off its earnings in 2008.Read Full Article Doctor Accused of Leak to Drug MakerA member of the Senate said that a diabetes expert tipped GlaxoSmithKline to the publication of safety questions about Avandia.Read Full Article GSK and AstraZeneca raided in EU probeThe European Union (EU) has raided the offices of GlaxoSmithKline and AstraZeneca as part of an investigation into whether pharmaceutical companies have abused patents to limit supplies of generic medicines.Read Full Article External News for: glaxosThe Safety of Glaxo's Diabetes Drug Avandia - TopNews United StatesVitals SpotlightThe Safety of Glaxo's Diabetes Drug AvandiaTopNews United StatesThat is when sales of the drug and shares of Glaxo declined. Also, the findings lead to a full-blown Congressional inquiry, highly stringent safety warnings ...Meet Glaxo's Fixer -- The Man Who Scuttles Drug Critics With One Phone CallBNETUS reviewers urge Glaxo's Avandia come off marketMoneycontrol.comall 901 news articles »The Safety of Glaxo's Diabetes Drug Avandia - TopNews United StatesVitals SpotlightThe Safety of Glaxo's Diabetes Drug AvandiaTopNews United StatesThat is when sales of the drug and shares of Glaxo declined. Also, the findings lead to a full-blown Congressional inquiry, highly stringent safety warnings ...Meet Glaxo's Fixer -- The Man Who Scuttles Drug Critics With One Phone CallBNETUS reviewers urge Glaxo's Avandia come off marketMoneycontrol.comall 901 news articles »FDA Warns About Glaxo's Asthma Drug; Novavax Boosted By Vaccine Study - DailyFinanceFDA Warns About Glaxo's Asthma Drug; Novavax Boosted By Vaccine StudyDailyFinance... came out of the US The new label warning isn't limited to Glaxo's meds; Novartis's (NVS) Foradil and AstraZeneca's (AZN) Symbicort are affected as well. ...and more »The Safety of Glaxo's Diabetes Drug Avandia - TopNews United StatesVitals SpotlightThe Safety of Glaxo's Diabetes Drug AvandiaTopNews United StatesThat is when sales of the drug and shares of Glaxo declined. Also, the findings lead to a full-blown Congressional inquiry, highly stringent safety warnings ...Meet Glaxo's Fixer -- The Man Who Scuttles Drug Critics With One Phone CallBNETUS reviewers urge Glaxo's Avandia come off marketMoneycontrol.comall 901 news articles »FDA Warns About Glaxo's Asthma Drug; Novavax Boosted By Vaccine Study - DailyFinanceFDA Warns About Glaxo's Asthma Drug; Novavax Boosted By Vaccine StudyDailyFinance... came out of the US The new label warning isn't limited to Glaxo's meds; Novartis's (NVS) Foradil and AstraZeneca's (AZN) Symbicort are affected as well. ...and more »Glaxo's plan to acquire 5% stake in Dr Reddy's may fizzle out - Economic TimesGlaxo's plan to acquire 5% stake in Dr Reddy's may fizzle outEconomic TimesNEW DELHI: UK-BASED GlaxoSmithKline's (GSK) plan to buy about 5% stake in Dr Reddy's Laboratories (DRL) for $150-160 million is stuck and unlikely to happen ...and more » |
i8news.com |
